Last updated: July 27, 2026
ecutive summary
Laboratoire HRA Pharma v. Teva (E.D. Pa. 1:15-cv-00045) is a Hatch-Waxman patent infringement case tied to an FDA product in HRA Pharma’s women’s health franchise. The docket reflects a standard Paragraph IV framework: HRA Pharma alleges Teva’s ANDA filing infringes one or more Orange Book-listed patents, and Teva contests infringement and/or invalidity. A litigation-focused outcome requires docket-level identifiers (patent numbers asserted, parties’ Markman rulings, claim construction, summary judgment, and settlement terms). Those case specifics are not present in the information provided here, so a complete and accurate litigation summary cannot be produced from the provided input alone.
Laboratoire HRA Pharma v. Teva 1:15-cv-00045 litigation summary: what patents were asserted and what happened
What did Laboratoire HRA Pharma accuse Teva of infringing in 1:15-cv-00045?
A complete infringement narrative depends on the specific Orange Book patents asserted in the complaint and the ANDA product Teva sought to market. Those particulars are not included in the provided reference to “Laboratoire HRA Pharma v. Teva Pharmaceuticals USA Inc.|1:15-cv-00045,” so the asserted patent claims cannot be enumerated.
Which patents and claims were at issue in the E.D. Pa. case?
A litigation analysis requires at minimum:
- the asserted patent numbers (utility and any method-of-use)
- claim numbers tied to the allegations
- the asserted theories (literal infringement, doctrine of equivalents)
- Teva’s non-infringement and invalidity arguments (35 USC §§ 102, 103, 112, 101 where raised)
Those elements are not available in the provided input, so the asserted estate cannot be mapped.
What arguments did Teva raise (invalidity, non-infringement, defenses)?
To analyze Teva’s case, a record is needed for:
- any claim construction positions (Markman)
- prior art references cited in Teva’s invalidity contentions
- expert report themes (e.g., obviousness motivation, enablement)
- any inequitable conduct or prosecution history estoppel theories
No docket or briefing detail is included, so Teva’s litigation posture cannot be characterized accurately.
What did the court decide on claim construction and key motions?
A credible litigation summary must include:
- claim construction results (which claim terms were construed and to what meaning)
- summary judgment decisions (infringement/invalidity)
- trial outcomes or dismissal/judgment entries
The provided input does not include orders or outcomes, so the procedural history cannot be restated.
How did the case end: trial verdict, settlement, or dismissal?
Ending status drives business impact: whether exclusivity was preserved by settlement timing, whether a generic launch was delayed, or whether a court enabled entry for specific claims. The input does not include a termination event (dismissal type, consent judgment, settlement agreement execution date, or remaining patents).
Hatch-Waxman Paragraph IV and Orange Book context for Laboratoire HRA Pharma v. Teva
What is the Orange Book status and Paragraph IV structure in this dispute?
A standard Paragraph IV case has a predictable shape:
- ANDA filed by Teva
- notice of Paragraph IV certification sent to the NDA holder
- suit filed within statutory timing window
- litigation stay triggered while the case is pending
But the drug identity and the Orange Book list of patents for that NDA are not provided in the prompt, so the exclusivity/patent linkage cannot be concretely tied to this case.
When would generic entry have been permitted under the statutory stay?
The entry date depends on:
- the filing date and timing of the suit
- the end of the 30-month stay
- the resolution of each asserted patent
- whether any court decision or consent judgment eliminated the stay
Without docket timeline and decision dates, the entry-risk window cannot be calculated.
Litigation impact analysis: what this means for Teva’s ANDA and HRA Pharma’s market exclusivity
What launch risks did Teva face under this case?
Launch risk depends on:
- strength of the asserted claims after construction
- whether the court issued non-infringement or invalidity rulings
- settlement scope (number of patents, permitted launch design-arounds)
No ruling or settlement scope is included in the provided input.
What did HRA Pharma gain or lose from the litigation outcome?
HRA Pharma’s gain is typically either:
- maintaining exclusivity through dismissal/ongoing injunction or
- extracting settlement consideration in exchange for delayed entry or limited product scope
No outcome details are available in the provided input.
Key takeaways
- The caption “Laboratoire HRA Pharma v. Teva Pharmaceuticals USA Inc. | 1:15-cv-00045” identifies the forum and parties but does not include the litigation specifics required for a correct patent-and-claims litigation summary.
- A litigation-grade analysis needs docket events (complaint asserted patents, claim construction, motions, final disposition, and settlement terms). Those are not present in the provided input.
- Any attempt to list asserted patents, describe court reasoning, or infer settlement outcomes from case number alone would be incomplete and not accurate.
FAQs
- What patents are commonly asserted in Laboratoire HRA Pharma v. Teva Hatch-Waxman cases?
- How does claim construction typically change infringement analysis in Paragraph IV cases like 1:15-cv-00045?
- What outcomes most often drive generic launch timing after a 30-month stay ends?
- What settlement terms usually control permitted generic design-arounds in HRA Pharma women’s health disputes?
- How should investors interpret a dismissal versus a consent judgment in ANDA patent cases?
References
- Federal Trade Commission. (n.d.). Hatch-Waxman Act overview and generic approval framework. FTC.
- U.S. District Court, Eastern District of Pennsylvania. (2015). Docket: Laboratoire HRA Pharma v. Teva Pharmaceuticals USA Inc., No. 1:15-cv-00045.
